Status:
UNKNOWN
Intact Vagal Innervation and Glucagon-like Peptide-1 (GLP-1) Effects
Lead Sponsor:
University Hospital, Gentofte, Copenhagen
Collaborating Sponsors:
University of Copenhagen
Conditions:
Vagotomy, Truncal
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The aim of this study is to investigate the role of transmission via the vagal nerve for the effect of Glucagon-like peptide-1 (GLP-1) in respect to gastric emptying, appetite and food intake. The hy...
Detailed Description
GLP-1 is a potent enterogastron and incretin hormone. It is rapidly inactivated by dipeptidyl peptidase IV so only 10-15% enters the systemic circulation. This has led to the hypothesis that GLP-1 int...
Eligibility Criteria
Inclusion
- truncal vagotomy
- normal hemoglobin
- informed consent
- Age, gender and weight matched controls
- normal hemoglobin
- informed consent
Exclusion
- type 1 diabetes mellitus or type 2 diabetes mellitus
- body mass index \> 30 kg/m2
- inflammatory bowel disease
- intestinal resection
- nephropathy (serum creatinine \> 150 µM and/or albuminuria)
- liver disease (ALAT and/or ASAT \> 2 x normal value)
- treatment with medicine which cannot be paused for 12 hours
Key Trial Info
Start Date :
July 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2012
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01176890
Start Date
July 1 2008
End Date
December 1 2012
Last Update
December 7 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Internal Medicine F' laboratory
Hellerup, Copenhagen, Denmark, 2900